By Michael Susin


AstraZeneca said it has launched Evinova, a separate health-tech business to offer its knowledge of clinical trial design and study delivery.

The Anglo-Swedish pharmaceutical giant on Monday said the business will deliver solutions at scale to trials sponsors, clinical-research organisations, care teams and patients.

"This will reduce the time and cost of developing new medicines, bring care closer to home for patients and reduce the burden on health systems," it said.

The company added that the first major collaborations with Parexel and Fortrea will enable Evinova's digital health solutions to be offered to their wide customer base.

"We believe Evinova's combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions," Chief Executive Pascal Soriot said.


Write to Michael Susin at


(END) Dow Jones Newswires

November 20, 2023 02:47 ET (07:47 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Da Gen 2024 a Feb 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Da Feb 2023 a Feb 2024 Clicca qui per i Grafici di Astrazeneca